Clinical Development Medical Schools Treatment 
Drug Target Review
JULY 1, 2024
As a non-opioid, SRP-001 also eliminates abuse potential, positioning it as a safer and effective drug candidate for the treatment of acute and neuropathic pain and migraine headache. How does SRP-001’s safety profile, especially concerning hepatotoxicity and nephrotoxicity, compare to other common pain medications?
Drug Target Review
JUNE 6, 2023
In this IO arena, we continue to search for additional treatments that can further benefit patients. Immune checkpoint inhibitors, a well-established class of IO treatments, are designed to improve the ability of T-cells to fight cancer by removing inhibitory or suppressive mechanisms that may dampen the anti-cancer functions of T cells.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
FEBRUARY 29, 2024
Nevertheless, the potential to pioneer and move the needle for patients with few treatment options drives me to push through. During my training, I saw US medical school admissions reach parity. Harnessing the non-clinical and clinical experience with gene therapy, she then joined Brain Neurotherapy Bio, Inc.
The Pharma Data
JANUARY 26, 2021
Gerard Short, MBBS, as Chief Medical Officer (CMO). As CMO, Dr. Short will be responsible for overseeing the clinical development of VarmX’s pipeline, including progression of its lead product, VMX-C001, into clinical proof of concept and registrational studies.
The Pharma Data
JUNE 7, 2023
“These longer-term results show the durable overall survival benefit of sacituzumab govitecan over traditional chemotherapy in pre-treated HR+/HER2- metastatic breast cancer,” said Sara Tolaney, MD, MPH, Chief of the Division of Breast Oncology at the Dana-Farber Cancer Institute, and Associate Professor of Medicine, Harvard Medical School. “At
The Pharma Data
DECEMBER 3, 2020
Monti is a pioneer in the research and development of neuroactive steroids known as pherines, which includes VistaGen’s intranasal treatment candidate PH94B for anxiety disorders and PH10 for depression. Zai Lab – Alan Sandler was appointed to the newly created role of president and head of Global Development in Oncology.
The Pharma Data
DECEMBER 15, 2020
In late 2020, the effort received $200,000 in seed funding from the Baker Department of Cardiometabolic Health at the University of Melbourne’s medical school. Treatment induced sustainable clinical responses and reduced systemic inflammation. Daratumumab already is approved for the treatment of multiple myeloma.
Expert insights. Personalized for you.
59 
Let's personalize your content